deltatrials
Completed PHASE1 NCT00002677

Tributyrin in Treating Patients With Refractory Prostate Cancer or Other Solid Tumors

PHASE I STUDY OF THE ORALLY ADMINISTERED BUTYRATE PRODRUG, TRIBUTYRIN, IN PATIENTS WITH SOLID TUMORS

Sponsor: National Cancer Institute (NCI)

Conditions Prostate Cancer Unspecified Adult Solid Tumor, Protocol Specific
Interventions chemotherapy tributyrin
Updated 9 times since 2017 Last updated: Oct 31, 2019 Started: Aug 31, 1995 Primary completion: Mar 31, 2003 Completion: Mar 31, 2003

A PHASE1 clinical study on Prostate Cancer and Unspecified Adult Solid Tumor, Protocol Specific, this trial is completed. The trial is conducted by National Cancer Institute (NCI) and has accumulated 9 data snapshots since 1995. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

9 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  4. Dec 2019 — Jan 2021 [monthly]

    Completed PHASE1

  5. Sep 2019 — Dec 2019 [monthly]

    Completed PHASE1

▶ Show 4 earlier versions

  1. Jun 2018 — Sep 2019 [monthly]

    Completed PHASE1

  2. Apr 2017 — Jun 2018 [monthly]

    Completed PHASE1

  3. Feb 2017 — Apr 2017 [monthly]

    Completed PHASE1

  4. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE1

    First recorded

Aug 1995

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
  • University of Maryland, Baltimore
Data source: University of Maryland, Baltimore

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Baltimore, United States